|
Reuters TORONTO, Oct 2 (Reuters) - Biovail Corp (NYSE:BVF)(NYSE:BVF) said on Tuesday it had filed with U.S. regulators to sell a melt-in-the-mouth antidepressant similar to Prozac, joining a long list of firms trying to muscle in on Eli Lilly (NYSE:LLY) & Co.`s lucrative franchise. The Canadian drug developer said its FlashDose formulation of fluoxetine, a leading Selective Serotonin Reuptake Inhibitor prescribed for depression, obsessive compulsive disorder and bulimia, is aimed at 15 percent of patients not able to swallow pills. Unlike generic drug developers, Biovail plans to show that its drug is different, and offers advantages over currently marketed fluoxetine products. Biovail is carving out a niche for itself by combining drug delivery technologies with proven, off-patent compounds to create drugs with fewer side effects. A handful of companies has filed with regulators to sell generic versions of Prozac, with Barr Laboratories Inc. (NYSE:BRL) winning approval for its 20-milligram capsule on Aug. 2, giving it 180 days on the market as the only generic version of Prozac. Prozac, launched in the United States in 1998, was the first of a revolutionary new class of antidepressants that coax serotonin, a brain messenger chemical, to remain in spaces surrounding nerve endings, instead of moving into nerve endings -- a process believed to stave off depression`s symptoms. Eli Lilly`s Prozac racked up about $2.8 billion in sales for the 12 months ended June 2001, but as much as 80 percent of these sales could end up in the hands of generics as health insurers look to cut costs. Shares of Biovail closed at $44.96 on Monday in New York, down slightly from a year high of $48.45, and have remained strong in the recent market downturn as investors deem its diversified revenue stream, and deep-drug pipeline as resilient to the ups and downs of the economy. ich kann zu der aktie noch nicht viel sagen, außer der chart sieht aus wie das kaisergebirge, muß mir das erst genau anschauen, wird auch in münchen gehandelt, kurz vor all time high. aber doppeltop verdächtig? |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | dosto (02.10.01 23:54:21) |
| Beitrag: | 24 von 125 (ID:4551673) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |